NCT06625541View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJ302-IM in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

AJ302-IM

7 cohorts (7 dose levels) of participants are planned to be dosed.

DRUG

Placebo

Matching placebo

Trial Locations (1)

33136

RECRUITING

AnnJi Investigational Site, Miami

Sponsors
All Listed Sponsors
lead

AnnJi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06625541 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJ302-IM in Healthy Volunteers | Biotech Hunter | Biotech Hunter